Abstract 80P
Background
HLX26 is a novel humanised anti-lymphocyte activation gene-3 monoclonal antibody. This study aimed to evaluate the safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab (a novel programmed cell death-1 inhibitor) in patients with advanced solid tumours.
Methods
This was a single-centre, open-label, dose-escalation phase 1 study. Patients with histologically or cytologically confirmed advanced/metastatic solid tumours that had failed or could not receive standard therapies were enrolled and received intravenous HLX26 at three dose levels (500, 800, 1600 mg) plus serplulimab (300 mg) Q3W, following a “3+3” design. The primary endpoint was dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) within three weeks after the first administration of HLX26 (i.e. the DLT observation period). Secondary endpoints included safety, preliminary efficacy, pharmacokinetics, and immunogenicity.
Results
As of 19 July 2023, 9 patients with primary stage IV non-small cell lung cancer (n=4, 44.4%), small cell lung cancer (n=2, 22.2%), gastric cancer (n=1, 11.1%), cervical cancer (n=1, 11.1%), or endometrial cancer (n=1, 11.1%) were enrolled and received HLX26 at 500 mg (n=3), 800 mg (n=3), or 1600 mg (n=3), in combination with 300 mg serplulimab. The median age was 66 years, and 6 (66.7%) patients were male. All patients experienced treatment-emergent adverse events (TEAEs); all TEAEs that occurred during the DLT observation period were grade 1 or 2. One patient in the 800 mg group reported grades 3 or 4 drug-related asthenia, pain, and neutrophil count decreased. No DLT was reported and the MTD was not determined yet. Among the 8 efficacy evaluable patients, none had achieved complete or partial response; 3 (37.5%) patients (one in each group) had a best overall response of stable disease.
Conclusions
No new safety signals were observed for the different doses of HLX26 in combination with serplulimab. HLX26 plus serplulimab was safe and well tolerated in patients with advanced solid tumours who had failed or could not receive standard therapies.
Clinical trial identification
NCT05400265 (released on 1 June 2022).
Editorial acknowledgement
Editorial assistance was provided by Zhi Hao Kwok, Shiqi Zhong, and Chen Hu of Shanghai Henlius Biotech, Inc.
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
H. Li, W. Kang, J. Li, Q. Wang, J. Zhu: Financial Interests, Personal, Full or part-time Employment: Shanghai Henlius Biotech, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract